tiprankstipranks
Gilead Sciences (MX:GILD)
:GILD
Mexico Market
GILD
Gilead Sciences
RESEARCH TOOLSreports

Gilead Sciences (GILD) Stock Forecast & Price Target

0 Followers
See the Price Targets and Ratings of:

GILD Analyst Ratings

Strong Buy
23Ratings
Strong Buy
19 Buy
4 Hold
0 Sell
Based on 23 analysts giving stock ratings to
Gilead
Sciences
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

GILD Stock 12 Month Forecast

Average Price Target

$2,775.84
▲(22.02% Upside)
Based on 23 Wall Street analysts offering 12 month price targets for Gilead Sciences in the last 3 months. The average price target is $2,775.84 with a high forecast of $3,139.77 and a low forecast of $2,093.18. The average price target represents a 22.02% change from the last price of $2,275.00.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"2041":"$2,041","3140":"$3,140","2315.75":"$2,315.8","2590.5":"$2,590.5","2865.25":"$2,865.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":3139.7721912,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$3.14K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":2775.8440508563635,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$2.78K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":2093.1814608000004,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$2.09K</span>\n  </div></div>","useHTML":true}}],"tickPositions":[2041,2315.75,2590.5,2865.25,3140],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2025","6":"Jan<br/>2026","9":"Apr<br/>2026","12":"Jul<br/>2026","25":"Jul<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2217.67,2288.6009377846153,2359.531875569231,2430.4628133538463,2501.3937511384615,2572.324688923077,2643.2556267076925,2714.1865644923078,2785.117502276923,2856.0484400615387,2926.979377846154,2997.910315630769,3068.841253415385,{"y":3139.7721912,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2217.67,2260.6064654504894,2303.542930900979,2346.4793963514685,2389.4158618019583,2432.3523272524476,2475.288792702937,2518.2252581534267,2561.161723603916,2604.0981890544053,2647.034654504895,2689.9711199553844,2732.907585405874,{"y":2775.8440508563635,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2217.67,2208.093958523077,2198.517917046154,2188.941875569231,2179.365834092308,2169.7897926153846,2160.2137511384617,2150.637709661539,2141.061668184616,2131.4856267076925,2121.9095852307696,2112.3335437538467,2102.7575022769233,{"y":2093.1814608000004,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":2046.986,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 55,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2089.632,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 66,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2047.318,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 43,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2042.974,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 56,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2171.515,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 46,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2233.999,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 47,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2195.005,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 41,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2373.108,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 53,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2435.561,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 50,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2510.75,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 48,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2213.156,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 41,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2264.809,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 58,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2217.67,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 53,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$3,140Average Price Target$2,776Lowest Price Target$2,093
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Barclays Analyst forecast on MX:GILD
Emily Field
Barclays
Barclays
$2,529.26
Hold
11.18%
Upside
Reiterated
07/29/26
Gilead Sciences (GILD) Receives a Hold from Barclays
Cantor Fitzgerald Analyst forecast on MX:GILD
Carter Gould
Cantor Fitzgerald
Cantor Fitzgerald
$2,703.69
Buy
18.84%
Upside
Reiterated
07/28/26
Analysts Conflicted on These Healthcare Names: Biogen (NASDAQ: BIIB), NeuroPace (NASDAQ: NPCE) and Gilead Sciences (NASDAQ: GILD)
UBS Analyst forecast on MX:GILD
Michael Yee
UBS
UBS
$3,052.56
Buy
34.18%
Upside
Reiterated
07/28/26
Michael Yee Reiterates Buy on Gilead, Citing Long-Acting HIV Pipeline and PrEP Advancements as Drivers of Durable Growth
Morgan Stanley Analyst forecast on MX:GILD
Terence Flynn
Morgan Stanley
Morgan Stanley
$2,895.57→$2,878.12
Buy
26.51%
Upside
Reiterated
07/27/26
Gilead price target lowered to $165 from $166 at Morgan StanleyGilead price target lowered to $165 from $166 at Morgan Stanley
RBC Capital Analyst forecast on MX:GILD
Brian Abrahams
RBC Capital
RBC Capital
$2,093.18
Hold
-7.99%
Downside
Reiterated
07/23/26
Gilead Sciences (GILD) Gets a Hold from RBC Capital
BMO Capital Analyst forecast on MX:GILD
Evan Seigerman
BMO Capital
BMO Capital
$3,035.11
Buy
33.41%
Upside
Assigned
07/23/26
Analysts Offer Insights on Healthcare Companies: Gilead Sciences (NASDAQ: GILD), Arrowhead Pharmaceuticals (NASDAQ: ARWR) and Align Tech (NASDAQ: ALGN)
Bernstein Analyst forecast on MX:GILD
Courtney Breen
Bernstein
Bernstein
$2,790.91
Buy
22.68%
Upside
Reiterated
07/22/26
Analysts' Top Healthcare Picks: AgomAb Therapeutics NV ADR (AGMB), Milestone Pharmaceuticals (MIST)
Goldman Sachs Analyst forecast on MX:GILD
Salveen Richter
Goldman Sachs
Goldman Sachs
$2,267.61
Hold
-0.32%
Downside
Reiterated
07/20/26
Gilead Sciences (GILD) Gets a Hold from Goldman Sachs
Leerink Partners Analyst forecast on MX:GILD
Daina Graybosch
Leerink Partners
Leerink Partners
$2,546.7→$2,215.28
Hold
-2.62%
Downside
Downgraded
07/20/26
Gilead downgraded to Market Perform from Outperform at LeerinkGilead downgraded to Market Perform from Outperform at Leerink
Citi Analyst forecast on MX:GILD
Geoff Meacham
Citi
Citi
$2,878.12
Buy
26.51%
Upside
Reiterated
07/15/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: Gilead Sciences (NASDAQ: GILD) and Johnson & Johnson (NYSE: JNJ)
Bank of America Securities Analyst forecast on MX:GILD
Tazeen Ahmad
Bank of America Securities
Bank of America Securities
$2,825.79
Buy
24.21%
Upside
Reiterated
07/13/26
Analysts Offer Insights on Healthcare Companies: Medtronic (NYSE: MDT), Quest Diagnostics (NYSE: DGX) and Gilead Sciences (NASDAQ: GILD)
Wells Fargo Analyst forecast on MX:GILD
Mohit Bansal
Wells Fargo
Wells Fargo
$2,878.12
Buy
26.51%
Upside
Reiterated
07/09/26
Wells Fargo Sticks to Their Buy Rating for Gilead Sciences (GILD)
J.P. Morgan Analyst forecast on MX:GILD
Chris Schott
J.P. Morgan
J.P. Morgan
$2,790.91
Buy
22.68%
Upside
Reiterated
07/09/26
Analysts Offer Insights on Healthcare Companies: Immunovant (NASDAQ: IMVT), Ionis Pharmaceuticals (NASDAQ: IONS) and Gilead Sciences (NASDAQ: GILD)
Truist Financial Analyst forecast on MX:GILD
Gregory Renza
Truist Financial
Truist Financial
$2,738.58→$2,721.14
Buy
19.61%
Upside
Reiterated
07/07/26
Gilead price target lowered to $156 from $157 at TruistGilead price target lowered to $156 from $157 at Truist
HSBC Analyst forecast on MX:GILD
Morten Herholdt
HSBC
HSBC
$2,319.94→$2,703.69
Buy
18.84%
Upside
Upgraded
07/06/26
Gilead upgraded to Buy from Hold at HSBCGilead upgraded to Buy from Hold at HSBC
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Barclays Analyst forecast on MX:GILD
Emily Field
Barclays
Barclays
$2,529.26
Hold
11.18%
Upside
Reiterated
07/29/26
Gilead Sciences (GILD) Receives a Hold from Barclays
Cantor Fitzgerald Analyst forecast on MX:GILD
Carter Gould
Cantor Fitzgerald
Cantor Fitzgerald
$2,703.69
Buy
18.84%
Upside
Reiterated
07/28/26
Analysts Conflicted on These Healthcare Names: Biogen (NASDAQ: BIIB), NeuroPace (NASDAQ: NPCE) and Gilead Sciences (NASDAQ: GILD)
UBS Analyst forecast on MX:GILD
Michael Yee
UBS
UBS
$3,052.56
Buy
34.18%
Upside
Reiterated
07/28/26
Michael Yee Reiterates Buy on Gilead, Citing Long-Acting HIV Pipeline and PrEP Advancements as Drivers of Durable Growth
Morgan Stanley Analyst forecast on MX:GILD
Terence Flynn
Morgan Stanley
Morgan Stanley
$2,895.57→$2,878.12
Buy
26.51%
Upside
Reiterated
07/27/26
Gilead price target lowered to $165 from $166 at Morgan StanleyGilead price target lowered to $165 from $166 at Morgan Stanley
RBC Capital Analyst forecast on MX:GILD
Brian Abrahams
RBC Capital
RBC Capital
$2,093.18
Hold
-7.99%
Downside
Reiterated
07/23/26
Gilead Sciences (GILD) Gets a Hold from RBC Capital
BMO Capital Analyst forecast on MX:GILD
Evan Seigerman
BMO Capital
BMO Capital
$3,035.11
Buy
33.41%
Upside
Assigned
07/23/26
Analysts Offer Insights on Healthcare Companies: Gilead Sciences (NASDAQ: GILD), Arrowhead Pharmaceuticals (NASDAQ: ARWR) and Align Tech (NASDAQ: ALGN)
Bernstein Analyst forecast on MX:GILD
Courtney Breen
Bernstein
Bernstein
$2,790.91
Buy
22.68%
Upside
Reiterated
07/22/26
Analysts' Top Healthcare Picks: AgomAb Therapeutics NV ADR (AGMB), Milestone Pharmaceuticals (MIST)
Goldman Sachs Analyst forecast on MX:GILD
Salveen Richter
Goldman Sachs
Goldman Sachs
$2,267.61
Hold
-0.32%
Downside
Reiterated
07/20/26
Gilead Sciences (GILD) Gets a Hold from Goldman Sachs
Leerink Partners Analyst forecast on MX:GILD
Daina Graybosch
Leerink Partners
Leerink Partners
$2,546.7→$2,215.28
Hold
-2.62%
Downside
Downgraded
07/20/26
Gilead downgraded to Market Perform from Outperform at LeerinkGilead downgraded to Market Perform from Outperform at Leerink
Citi Analyst forecast on MX:GILD
Geoff Meacham
Citi
Citi
$2,878.12
Buy
26.51%
Upside
Reiterated
07/15/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: Gilead Sciences (NASDAQ: GILD) and Johnson & Johnson (NYSE: JNJ)
Bank of America Securities Analyst forecast on MX:GILD
Tazeen Ahmad
Bank of America Securities
Bank of America Securities
$2,825.79
Buy
24.21%
Upside
Reiterated
07/13/26
Analysts Offer Insights on Healthcare Companies: Medtronic (NYSE: MDT), Quest Diagnostics (NYSE: DGX) and Gilead Sciences (NASDAQ: GILD)
Wells Fargo Analyst forecast on MX:GILD
Mohit Bansal
Wells Fargo
Wells Fargo
$2,878.12
Buy
26.51%
Upside
Reiterated
07/09/26
Wells Fargo Sticks to Their Buy Rating for Gilead Sciences (GILD)
J.P. Morgan Analyst forecast on MX:GILD
Chris Schott
J.P. Morgan
J.P. Morgan
$2,790.91
Buy
22.68%
Upside
Reiterated
07/09/26
Analysts Offer Insights on Healthcare Companies: Immunovant (NASDAQ: IMVT), Ionis Pharmaceuticals (NASDAQ: IONS) and Gilead Sciences (NASDAQ: GILD)
Truist Financial Analyst forecast on MX:GILD
Gregory Renza
Truist Financial
Truist Financial
$2,738.58→$2,721.14
Buy
19.61%
Upside
Reiterated
07/07/26
Gilead price target lowered to $156 from $157 at TruistGilead price target lowered to $156 from $157 at Truist
HSBC Analyst forecast on MX:GILD
Morten Herholdt
HSBC
HSBC
$2,319.94→$2,703.69
Buy
18.84%
Upside
Upgraded
07/06/26
Gilead upgraded to Buy from Hold at HSBCGilead upgraded to Buy from Hold at HSBC
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
BBOTBridgeBio Oncology Therapeutics
AVBPArriVent BioPharma, Inc.
BTSGBrightSpring Health Services, Inc.
MLYSMineralys Therapeutics, Inc.
AMLXAmylyx Pharmaceuticals Inc
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Gilead Sciences

3 Months
Tyler Van BurenTD Cowen
Success Rate
25/31 ratings generated profit
81%
Average Return
+7.72%
Copying Tyler Van Buren's trades and holding each position for 3 Months would result in 80.65% of your transactions generating a profit, with an average return of +7.72% per trade.
1 Year
Geoff MeachamCiti
Success Rate
22/24 ratings generated profit
92%
Average Return
+24.02%
Copying Geoff Meacham's trades and holding each position for 1 Year would result in 91.67% of your transactions generating a profit, with an average return of +24.02% per trade.
2 Years
Tyler Van BurenTD Cowen
Success Rate
30/31 ratings generated profit
97%
Average Return
+42.24%
Copying Tyler Van Buren's trades and holding each position for 2 Years would result in 96.77% of your transactions generating a profit, with an average return of +42.24% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

GILD Analyst Recommendation Trends

Rating
Mar 26
Apr 26
May 26
Jun 26
Jul 26
Strong Buy
0
0
0
0
0
Buy
50
48
41
58
53
Hold
10
13
12
13
13
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
60
61
53
71
66
In the current month, GILD has received 53 Buy Ratings, 13 Hold Ratings, and 0 Sell Ratings. GILD average Analyst price target in the past 3 months is 2,775.84.
Each month's total comprises the sum of three months' worth of ratings.

GILD Financial Forecast

GILD Earnings Forecast

Next quarter’s earnings estimate for GILD is -$126.64 with a range of -$138.32 to -$111.64. The previous quarter’s EPS was $35.41. GILD beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.95% of the time in the same period. In the last calendar year GILD has Performed in-line its overall industry.
Next quarter’s earnings estimate for GILD is -$126.64 with a range of -$138.32 to -$111.64. The previous quarter’s EPS was $35.41. GILD beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.95% of the time in the same period. In the last calendar year GILD has Performed in-line its overall industry.

GILD Sales Forecast

Next quarter’s sales forecast for GILD is $129.08B with a range of $125.21B to $131.12B. The previous quarter’s sales results were $121.82B. GILD beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 49.05% of the time in the same period. In the last calendar year GILD has Performed in-line its overall industry.
Next quarter’s sales forecast for GILD is $129.08B with a range of $125.21B to $131.12B. The previous quarter’s sales results were $121.82B. GILD beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 49.05% of the time in the same period. In the last calendar year GILD has Performed in-line its overall industry.

GILD Stock Forecast FAQ

What is MX:GILD’s average 12-month price target, according to analysts?
Based on analyst ratings, Gilead Sciences’s 12-month average price target is 2,775.84.
    What is MX:GILD’s upside potential, based on the analysts’ average price target?
    Gilead Sciences has 22.02% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is Gilead Sciences a Buy, Sell or Hold?
          Gilead Sciences has a consensus rating of Strong Buy, which is based on 19 buy ratings, 4 hold ratings and 0 sell ratings.
            What is Gilead Sciences’s share price target?
            The average share price target for Gilead Sciences is 2,775.84. This is based on 23 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst share price target is $3,139.77 ,and the lowest forecast is $2,093.18. The average share price target represents 22.02% Increase from the current price of $2,275.
              What do analysts say about Gilead Sciences?
              Gilead Sciences’s analyst rating consensus is a Strong Buy. This is based on the ratings of 23 Wall Streets Analysts.
                How can I buy shares of Gilead Sciences?
                To buy shares of MX:GILD, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.